Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15236878.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sensory neural hearing loss (SNHL) was evaluated in the patients who were treated with concurrent chemoradiation therapy for nasopharyngeal carcinoma. Ten from 48 ears showed persistent SNHL. Radiotherapy techniques, radiation dose to inner ear and post-treatment otitis media were significant predicting factors for SNHL.
Medical subject headings
- Carcinoma
- Cisplatin
- Hearing Loss, Sensorineural
- Nasopharyngeal Neoplasms
- Radiation Injuries